Merck & Co Could Be Plotting $30bn Bid For Seagen

Regulatory Concerns Remain

 
• By Andrew McConaghie
  
Seagen
A $30bn plus buy out would also be welcomed by the wider biotech sector, where M&A could help turnaround negative investor sentiment. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip